Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
The top analyst upgrades, downgrades and initiations seen on Friday morning include AK Steel, Alphabet, Amazon, Boeing, ConocoPhilllips, Nokia and Twitter.
Most investors either feel the stock market needs a breather or that they are going to find their next real rewards in some of the companies that are not going to just move up or down with the Dow or...
Thursday's top analyst upgrades, downgrades and initiations include Chesapeake Energy, Rite Aid, Harley-Davidson, Toll Brothers and Transocean.
With a week that saw the end of April and a ton of volatility, we also saw some big insider selling hit the tape.
Agenus, in conjunction with Incyte, announced a global license for the development and commercialization of Agenus's proprietary Retrocyte Display antibody discovery platform.
Source: ThinkstockA malaria vaccine is supposed to be a good thing. Right? Unfortunately that all depends. GlaxoSmithKline PLC (NYSE: GSK) currently plans to seek marketing approval for the first...
Today’s version of the BioHealth Business Daily is rather different as we have a big disappointment from one of the top biotech operations in the world.  BioHealth stocks moving on news and after...
Antigenics Inc. (NASDAQ: AGEN) has announced this morning that it has entered into definitive agreements to sell 7 million shares of its common stock at a price of $3.00 per share in a private...
Antigenics Inc.  (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this morning. Shares are down almost 7% to $2.17. The 52 week...
Antigenics (AGEN-NASDAQ) saw its shares pop more than 20% as it released data in apress release regarding its Oncophage trials. The company’s follow-up ‘end of study’ data on Phase...
It wasn’t all that long ago that we were dicussing the implosion of the CBOE Volatility Index (the VIX) as it was trying to suck its way to under 10.0 for the first time since the...
by H.S. AyoubBioHealth Investor.com
by H.S. AyoubBioHealth Investor.com Biotechnology GENETIC TECH SPON [GENE] +48.22% DENDREON CORP [DNDN] +19.69% CORCEPT THERAPEUTICS [CORT] +15.70% ANTIGENICS INC [AGEN] +14.83% REXAHN PHARMACEUTICL...